These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18373403)

  • 21. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.
    Nelson HD; Huffman LH; Fu R; Harris EL;
    Ann Intern Med; 2005 Sep; 143(5):362-79. PubMed ID: 16144895
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
    Hartenbach EM; Becker JM; Grosen EA; Bailey HH; Petereit DG; Laxova R; Schink JC
    Genet Test; 2002; 6(2):75-8. PubMed ID: 12229876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling.
    Butrick M; Kelly S; Peshkin BN; Luta G; Nusbaum R; Hooker GW; Graves K; Feeley L; Isaacs C; Valdimarsdottir HB; Jandorf L; DeMarco T; Wood M; McKinnon W; Garber J; McCormick SR; Schwartz MD
    Genet Med; 2015 Jun; 17(6):467-75. PubMed ID: 25232856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.
    Steffen LE; Du R; Gammon A; Mandelblatt JS; Kohlmann WK; Lee JH; Buys SS; Stroup AM; Campo RA; Flores KG; Vicuña B; Schwartz MD; Kinney AY
    Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1772-1780. PubMed ID: 28971986
    [No Abstract]   [Full Text] [Related]  

  • 30. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.
    Lerman C; Biesecker B; Benkendorf JL; Kerner J; Gomez-Caminero A; Hughes C; Reed MM
    J Natl Cancer Inst; 1997 Jan; 89(2):148-57. PubMed ID: 8998184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
    Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
    Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
    Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
    Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation and outcomes of telephone disclosure of clinical BRCA1/2 test results.
    Patrick-Miller L; Egleston BL; Daly M; Stevens E; Fetzer D; Forman A; Bealin L; Rybak C; Peterson C; Corbman M; Bradbury AR
    Patient Educ Couns; 2013 Dec; 93(3):413-9. PubMed ID: 24075727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
    Forman AD; Hall MJ
    Breast J; 2009; 15 Suppl 1():S56-62. PubMed ID: 19775331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
    JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Testing for hereditary breast and ovarian cancer in the southeastern United States.
    Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
    Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Breast cancer and ovarian cancer genetics.
    Edlich RF; Winters KL; Lin KY
    J Long Term Eff Med Implants; 2005; 15(5):533-45. PubMed ID: 16218901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.
    Isselhard A; Töpper M; Berger-Höger B; Steckelberg A; Fischer H; Vitinius F; Beifus K; Köberlein-Neu J; Wiedemann R; Rhiem K; Schmutzler R; Stock S
    Trials; 2020 Jun; 21(1):501. PubMed ID: 32513307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.
    Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM
    Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer.
    Calzone KA; Prindiville SA; Jourkiv O; Jenkins J; DeCarvalho M; Wallerstedt DB; Liewehr DJ; Steinberg SM; Soballe PW; Lipkowitz S; Klein P; Kirsch IR
    J Clin Oncol; 2005 May; 23(15):3455-64. PubMed ID: 15908654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.